AR and prostate carcinoma: The clinically used androgen receptor (AR) antagonistsfor thetreatment of prostate cancer (PCa) are all targeting the AR ligandbinding pocket (LBP), resulting in various drug-resistant problems.Therefore, a new strategy to combat PCa is urgently needed.